

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: IN01481KB	SERIAL NO.: To Be Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT: Anandan Palani et al.	
				FILING DATE: July 21, 2003	GROUP: To Be Assigned

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
	AA	5,952,349	09/14/99	Theodros Asberom et al.	514	316	
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						

FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	AK	WO 02/081449	10/17/02	PCT	C07D	211/58		
	AL	WO 98/01425	01/15/98	PCT	C07D	211/58		
	AM	EP 0 855 999	10/04/01	Europe	C07D	211/44		
	AN	WO 97/24324	07/10/97	PCT	C07D	211/44		
	AO	EP 0 151 824	08/21/85	Europe	C07D	471/04		
	AP	WO 01/30348	05/03/01	PCT	A61K	31/445		
	AQ	WO 01/77101	10/18/01	PCT	C07D	401/04		
	AR	WO 02/081449	10/17/02	PCT	C07D	211/58		

OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>	
	AS Anandan Palani et al., "Discovery of 4-[(Z)-(4-Bromophenyl)-(ethoxyimino)methyl]-1'-[(2,4--dimethyl-3-pyridinyl)carbonyl]-4'-methyl-1,4'-bipiperidine N-Oxide (SCH 351125): An Orally Bioavailable Human CCR5 Antagonist for the Treatment of HIV Infection", Journal of Medicinal Chemistry, vol. 44, No. 21, October 11, 2001, pgs. 3339-3342
	AT
	AU
	AV
	AW
	AX

EXAMINER	DATE CONSIDERED 10/20/05
----------	---

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.